MedTrace Logo

R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions

NCT01616329 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2022-05-11

No results posted yet for this study

Summary

Alloantibodies can lead to serious clinical consequences and logistic problems like obtaining properly and timely matched blood for the patients who do develop these antibodies. Prevention of such serious events is possible by extended matching and typing of donor's blood against the patient's for all the possible antigens, but this process is cumbersome and costly. Identifying a high risk group will be a feasible first target for advanced matching a big step forward, and the aim of the investigators study. The aim of the project is to examine the association between clinical, environmental and genetic characteristics of the recipient of erythrocyte transfusions and the risk or resistance to immunization against erythrocyte alloantigens that he/she was exposed to during that transfusion episode.

Conditions

  • Hemolysis

Sponsors & Collaborators

  • Leiden University Medical Center

    collaborator OTHER

  • Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research

    lead OTHER

Principal Investigators

  • Johanna van der Bom, MD Phd · Sanquin- LUMC, Leiden

  • Jaap Jan Zwaginga, MD Phd · Sanquin-Lumc, Leiden

  • Dorothea Evers, MD MSc · LUMC Leiden

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2017-08-31
Completion
2017-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01616329 on ClinicalTrials.gov